#Shanghai #USA #Lilly #XtalPi #Ailux

Ailux and Lilly Join Forces in Bispecific Antibody Development

Ailux, a subsidiary of XtalPi and an innovator in AI-driven biologics, has recently unveiled a strategic partnership with Eli Lilly and Company aimed at advancing the development of bispecific antibodies. This collaboration, announced on November 5, 2025, emphasizes the integration of cutting-edge technologies to tackle a variety of diseases.

Strategic Initiative for Advanced Therapeutics

Through this new agreement, Lilly will gain access to Ailux's groundbreaking AI-powered bispecific antibody engineering platform. This platform is designed to merge advanced structural modeling, generative design, and developability analytics, enabling the creation of novel therapeutic constructs characterized by enhanced efficacy and optimal drug-like properties.

Among the terms of this collaboration, Lilly has the opportunity to nominate a number of target pairs for the design of bispecific antibodies, alongside securing a license to utilize Ailux's proprietary platform internally. The financial metrics of the agreement reveal significant investment, with initial payments and options for future licensing summing up to a double-digit million-dollar figure. Importantly, the overall potential value of this collaboration could escalate to as much as $345 million, contingent upon various development, regulatory, and commercial milestones.

A Trustworthy Relationship

"Lilly has been a long-time partner of ours and we take pride in expanding this trusted relationship into the biologics sector," indicated Jian Ma, PhD, CEO of XtalPi. He further elaborated on the potential of their AI-powered technologies to facilitate the creation of transformative therapies.

Ailux's CEO, Alex (Yi) Li, expressed enthusiasm regarding the collaboration, stating, "Bispecific antibodies represent one of the most promising avenues in today's therapeutic milieu. Our AI-driven solutions are capable of swiftly altering panels of monospecific antibodies to produce bispecifics with superior efficacy and developability. Partnering with Lilly, a recognized leader in the field of biotherapeutics, marks a significant step toward introducing next-generation molecules into clinical settings."

About Ailux

Ailux is dedicated to the innovation of biologics focused on creating advanced therapeutic solutions powered by artificial intelligence. This subsidiary acts as XtalPi’s specialized platform for biologics development, combining proprietary computational models with cutting-edge laboratory capabilities. The team's mission includes addressing previously undruggable targets and developing molecules with unique therapeutic profiles. Comprising over 100 members globally, Ailux collaborates with prominent biopharmaceutical entities to convert pioneering research into effective medicines.

The XtalPi Vision

Founded by three physicists from MIT in 2015, XtalPi Holdings Limited operates at the forefront of research and development, harnessing the synergy of quantum physics, artificial intelligence, and robotics. This innovative platform amalgamates first-principles calculations with AI algorithms, advanced cloud computing, and standardized automation systems to provide digital and intelligent RD solutions across various industries including pharmaceuticals, materials science, energy, and more.

In summary, this collaboration between Ailux and Lilly reflects a significant advancement in the pursuit of innovative therapies, leveraging AI technologies to reshape the landscape of biopharmaceutical development. The potential benefits promised by this partnership may not only set new benchmarks in treatment efficacy but also redefine the mechanisms behind bispecific antibody development.